{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:36:59Z","timestamp":1791423419344,"version":"4.3.3"},"reference-count":21,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<jats:bold>s<\/jats:bold><\/jats:title><jats:p>The availability of doravirine (DOR) allowed clinicians to prescribe a dolutegravir (DTG)\u2010based two\u2010drug regimen (2DR) in individuals not eligible to receive lamivudine (3TC) or rilpivirine (RPV). The aims of this study were to describe the durability of DTG\u2009+\u2009DOR compared with DTG\/3TC and DTG\/RPV and the rate of virological failure and target not\u2010detected maintenance over time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective, monocentric analysis included all subjects who started a DTG\u2010based 2DR from 2018 to 2022 as a simplification. Descriptive statistics and non\u2010parametric tests to describe and compare the groups were applied. Kaplan\u2013Meier probability curves and Cox regression models for regimens durability were used.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study enrolled 710 individuals: 499 treated with DTG\/3TC, 140 with DTG\/RPV, and 71 with DTG\u2009+\u2009DOR. A 2DR with DOR was prescribed to older subjects who had a longer infection, greater exposure to different antiretroviral regimens, a higher proportion of resistance\u2010associated mutations, and a worse immune\u2010virologic status. Over a cumulative follow\u2010up of 68\u2009152\u2009weeks, 42 discontinuations were registered (5.9%). DTG\u2009+\u2009DOR had a risk of treatment interruption of 7.8% at 48\u2009weeks and 9.8% at 96\u2009weeks, significantly higher than the other 2DRs. In the multivariate Cox model, DTG\u2009+\u2009DOR and DTG\/RPV were significantly associated with discontinuation. The maintenance of target not detected during follow\u2010up was similar among groups. The rate of virological failure was higher for DTG\u2009+\u2009DOR through different event definitions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>DTG\u2009+\u2009DOR durability was high over a long follow\u2010up albeit lower than for other 2DRs. This combination might be an effective option in people with HIV that has proven difficult to treat.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.13615","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T07:29:38Z","timestamp":1706081378000},"page":"675-683","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Durability of doravirine with dolutegravir dual regimen compared with other dolutegravir\u2010based dual combinations"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4965-8789","authenticated-orcid":false,"given":"Roberto","family":"Rossotti","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases ASST Grande Ospedale Metropolitano Niguarda  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"D'Amico","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases ASST Grande Ospedale Metropolitano Niguarda  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas Brian","family":"Bana","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases ASST Grande Ospedale Metropolitano Niguarda  Milan Italy"},{"name":"School of Medicine University of Milan\u2010Bicocca  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Nava","sequence":"additional","affiliation":[{"name":"Clinical Microbiology ASST Grande Ospedale Metropolitano Niguarda  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Francesco","family":"Rezzonico","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases ASST Grande Ospedale Metropolitano Niguarda  Milan Italy"},{"name":"School of Medicine University of Pavia  Pavia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Raimondi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases ASST Grande Ospedale Metropolitano Niguarda  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Fanti","sequence":"additional","affiliation":[{"name":"Clinical Microbiology ASST Grande Ospedale Metropolitano Niguarda  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Gerolamo","family":"Chianura","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases ASST Grande Ospedale Metropolitano Niguarda  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Moioli","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases ASST Grande Ospedale Metropolitano Niguarda  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Vismara","sequence":"additional","affiliation":[{"name":"Clinical Microbiology ASST Grande Ospedale Metropolitano Niguarda  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Puoti","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases ASST Grande Ospedale Metropolitano Niguarda  Milan Italy"},{"name":"School of Medicine University of Milan\u2010Bicocca  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,23]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1887135"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2019.1577821"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1179\/1528433614Z.0000000015"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232473"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab429"},{"key":"e_1_2_11_7_1","unstructured":"US Department of Health and Human Services Food and Drug Administration.FDA approval letter: Pifeltro (doravirine).https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210806Orig1s000 210807Orig1s000Approv.pdf (accessed: July 20 2023)."},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-018-0497-3"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002496"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0458-4"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad100"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.02.007"},{"key":"e_1_2_11_13_1","first-page":"559","article-title":"2022 update of the drug resistance mutations in HIV\u20101","volume":"30","author":"Wensing AM","year":"2022","journal-title":"Top Antivir Med"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac036"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac130"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002449"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028488"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/09564624221116533"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010\u2010023\u201002075\u2010y"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003248"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.637910"},{"key":"e_1_2_11_22_1","unstructured":"U.S. National Library of Medicine.clinicaltrials.gov. Efficacy of Doravirine\u2009+\u2009Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch (DORDOL).https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04892654(accessed: August 01 2023)."}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13615","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T06:21:09Z","timestamp":1717568469000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.13615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,23]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/hiv.13615"],"URL":"https:\/\/doi.org\/10.1111\/hiv.13615","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,23]]},"assertion":[{"value":"2023-10-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}